Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;35(9):943-952.
doi: 10.1007/s10822-021-00408-3. Epub 2021 Jul 8.

A theoretical approach for the acylation/deacylation mechanisms of avibactam in the reversible inhibition of KPC-2

Affiliations

A theoretical approach for the acylation/deacylation mechanisms of avibactam in the reversible inhibition of KPC-2

Ignacio Lizana et al. J Comput Aided Mol Des. 2021 Sep.

Abstract

Klebsiella pneumoniae carbapenemase (KPC-2) is the most commonly encountered class A β-lactamase variant worldwide, which confer high-level resistance to most available antibiotics. In this article we address the issue by a combined approach involving molecular dynamics simulations and hybrid quantum mechanics/molecular mechanics calculations. The study contributes to improve the understanding, at molecular level, of the acylation and deacylation stages of avibactam involved in the inhibition of KPC-2. The results show that both mechanisms, acylation and deacylation, the reaction occur via the formation of a tetrahedral intermediate. The formation of this intermediate corresponds to the rate limiting stage. The activation barriers are 19.5 kcal/mol and 23.0 kcal/mol for the acylation and deacylation stages, respectively. The associated rate constants calculated, using the Eyring equation, are 1.2 × 10-1 and 3.9 × 10-4 (s-1). These values allow estimating a value of 3.3 × 10-3 for the inhibition constant, in good agreement with the experimental value.

Keywords: Avibactam; Inhibition; KPC-2; QM/MM.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Representative structure of the active site taken at 65 ns for the neutral form
Scheme 1
Scheme 1
Proposed inhibition mechanisms for class A β-lactamases
Fig. 2
Fig. 2
3-D view of the potential energy surface for the first stage of mechanism A
Fig. 3
Fig. 3
Structure of the transition state TS-A1 in the active site
Fig. 4
Fig. 4
Structure of the tetrahedral intermediate INT
Fig. 5
Fig. 5
3-D view of the PES-A2 corresponding to the second stage of the mechanism A
Fig. 6
Fig. 6
3-D view of the PES-B for the acylation of avibactam according to the mechanism B
Fig. 7
Fig. 7
Structure of the transition state for the acylation of avibactam according to the mechanism B
Fig. 8
Fig. 8
Structure of the acylated avibactam in the active site
Fig. 9
Fig. 9
Potential energy profile for the avibactam acylation pathway. Green: mechanism A; light blue: mechanism B
Fig. 10
Fig. 10
Orientations of the Ser129(O–H)–(N)Lys72 and N6–H–(O)Ser129 angles during the simulation
Fig. 11
Fig. 11
Clustering analysis in terms of the dihedral angles α, β and γ. The red dot represents the centroids
Fig. 12
Fig. 12
Structure corresponding to the centroid taken at 29 ns
Scheme 2
Scheme 2
Mechanism of recyclization of avibactam from its complex with KPC-2
Fig. 13
Fig. 13
3-D view of the PES-C1, corresponding to the formation of the tetrahedral intermediate
Fig. 14
Fig. 14
3-D view of the tetrahedral intermediate INT
Fig. 15
Fig. 15
3-D view of the transition state TS-C1
Fig. 16
Fig. 16
2-D view of the PES-C2, corresponding to the recyclization of avibactam
Fig. 17
Fig. 17
3-D view of the transition state TS-C2
Fig. 18
Fig. 18
Potential energy profile along the avibactam deacylation pathway
Scheme 3
Scheme 3
Representation of the acylation/deacylation cycle of avibactam with KPC-2

References

    1. World Health Organization (2020) Antimicrobial resistance. World Health Organization, Geneva. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
    1. World Health Organization (2020) Lack of new antibiotics threatens global efforts to contain drug-resistant infections. World Health Organization, Geneva. https://www.who.int/news/item/17-01-2020-lack-of-new-antibiotics-threate...
    1. Centers for Disease Control and Prevention (2019) Biggest threats and data. Centers for Disease Control and Prevention, Atlanta. https://www.cdc.gov/drugresistance/biggest-threats.html
    1. Centers for Disease Control and Prevention (2020) About antibiotic resistance. Centers for Disease Control and Prevention, Atlanta. https://www.cdc.gov/drugresistance/about.html
    1. Aminov RI. Front Microbiol. 2010;1(134):134. - PMC - PubMed

Publication types

MeSH terms